Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
PDSB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.29
Previous CloseN/A
Volume197.50K
Average Volume (3M)467.79K
Market Cap
$49.82M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Aug 13, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding45,710,000
10 Day Avg. Volume331,514
30 Day Avg. Volume467,788
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.50Price Target Upside588.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe Versamune HPV + pembrolizumab combination exceeds benchmarks for median overall survival and objective response rates in HPV16+ HNSCC patients.
Clinical TrialsPDS01ADC meets study enrollment milestone; expansion progresses into Stage 2 for colorectal cancer cohort.
Market PotentialThe prevalence of HPV16 in U.S. R/M HNSCC is estimated at 40-60%, with U.S. and EU prevalence expected to exceed 60%, highlighting the substantial market for effective treatments.
Bears Say
Financial ChallengesThe company announced the start of its Phase 3 VERSATILE-003 study, a pivotal trial to evaluate the safety and efficacy of Versamune HPV in combination with pembrolizumab as a first-line treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma, requiring significant capital investment.
Funding RequirementsThe company expressed a need to explore additional funding opportunities to complete select ongoing operations, including the VERSATILE-003 trial.
PDS Biotechnology News
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $0.85 and its highest was $4.29 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $49.82M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Aug 13, 2025 which is in 10 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on May 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.247 by $0.037.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.23.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 45,710,000 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.247. Following the earnings report the stock price went up 3.15%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (588.07% Upside)
$7.50 (588.07% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.25%
12-Months-Change
Fundamentals
Return on Equity
-119.22%
Trailing 12-Months
Asset Growth
-31.85%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology (PDSB) is a clinical-stage biopharmaceutical company specializing in the development of immunotherapy-based cancer treatments and infectious disease vaccines. Utilizing its proprietary Versamune® technology platform, PDS Biotech focuses on creating novel therapies that activate the immune system to recognize and combat various forms of cancer. The company's primary goal is to bring innovative treatments to market that improve patient outcomes and quality of life.
PDSB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with significant progress in clinical trials, especially with the initiation of the VERSATILE 003 Phase 3 trial and promising Phase 2 results. Financial metrics show improvement, but operational costs and cash flow remain challenges.Read More>PDSB Stock 12 Month Forecast
Average Price Target
$7.50
▲(588.07%Upside)
Technical Analysis
CytomX Therapeutics
―
Cue Biopharma
―
Sutro Biopharma
―
PMV Pharmaceuticals
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
0.33% Insiders
4.27% Mutual Funds
0.22% Other Institutional Investors
91.73% Public Companies and
Individual Investors